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Coronaviruses (CoVs) are a large family of 
enveloped, single-stranded, zoonotic RNA viruses 
that represent one of the major pathogens that 
primarily targets the respiratory system. CoVs are 
divided into 4 genera: alpha, beta, delta, and 
gamma; alpha and beta CoVs are known to infect 
humans (human coronaviruses - HCoVs).1 They 
resulted previously in the severe acute respiratory 
syndrome coronavirus (SARS-CoV) and Middle 
East respiratory syndrome coronavirus (MERS-
CoV).2  Since December 2019, a novel CoV (SARS-
CoV-2) started to cause infections in humans, first 
reported in Wuhan, Hubei province, China, with a 
cluster of patients presenting with pneumonia. 
Afterwards, the novel CoV has quickly spread 
throughout the world.3,4 
Genomic analyses suggest that the 2019-nCoV 
sequencing is closely related to the bat SARS-
related CoV, but the pathogen was probably 
transmitted to humans by other animals which may 
have served as intermediate hosts facilitating the 
virus recombination and mutation, further adding to 
its genetic diversity.5,6Two different types of 2019-
nCoV were identified, designated type L 
(accounting for 70 % of the strains) and type S 
(accounting for 30 %) but the difference between 
the two strains and clinical implications remain to 
be determined. The L type predominated during the 
early days of the epidemic in China but accounted 
for a lower proportion of strains outside of Wuhan.7 
 
Infectivity and clinical presentation 
Droplet transmission with the virus released in the 
respiratory secretions is the main mode of 
transmission, with increasing evidence towards 
aerosol transmission as well, while feco-oral 
transmission has not been documented yet.8,9 Based 
on the published reports, the incubation period 
ranges between 1-24 days (median three days) and 
the median duration of viral RNA shedding from 
oropharyngeal specimens is 20 days (range of 8 to 
37 days).6,8 
The initial clinical sign of novel coronavirus 
disease 2019 (COVID-19) which allowed case 
detection was pneumonia. However, similar to 
other HCOVs, 2019-nCoV causes a wide spectrum 
of clinical manifestations in humans, ranging from 
a common cold like symptoms to more severe 
disease as pneumonia, severe acute respiratory 
distress syndrome, multiorgan failure and even 
death. The most common symptoms at onset are 
fever, cough, and fatigue, while other symptoms 
include sputum production, headache, hemoptysis 
and dyspnea. Gastrointestinal symptoms have also 
been reported.9,10  
Preliminary evidence suggests that children are 
as likely as adults to become infected with 2019-
nCoV but are less likely to be symptomatic or 
develop severe symptoms, which mean that 
children might not be tested for 2019-nCoV as 
frequently as adults. However, the importance of 
children remains in their ability to transmit 
infections even in asymptomatic cases.11,12 On the 
other hand, older people and people of all ages with 
severe chronic medical conditions like heart 
disease, lung disease and diabetes, seem to be 
at higher risk of developing serious COVID-19 
illness and have higher risk of COVID-19 related 
death.13 
Data from China and USA reports suggest that a 
majority of COVID-19 related deaths have occurred 
among adults aged ≥60 years, particularly those 
aged above 85 years and those with underlying 
serious health conditions.14,15  The period from the 
onset of COVID-19 symptoms to death ranged from 
6 to 41 days with a median duration of 14 days.16 
ARDS is the main cause of death in COVID-19. 
One of the main mechanisms for ARDS is the 
cytokine storm with uncontrolled systemic 
inflammatory response resulting from the release of 
large amounts of pro-inflammatory cytokines (IFN-
α, IFNγ-, IL-1b, IL-6, TNF- α, etc.) and chemokines 
leading to ARDS and multiple organ failure (figure 
1). This feature might represent under-recognized 
secondary hemophagocytic lymphohistiocytosis 
(sHLH).17 Although the virus stimulates both 
humoral and cellular immune mechanisms, 
however data showed that both CD4+ and CD8+ T 
cells, although activated, are significantly reduced 
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Figure 1. Postulated pathogenesis of SARS-CoV-2 infection (Quoted from Jin et al, 2020)19 
ACE2: angiotensin-converting enzyme 2; ADE: Antibody-dependent enhancement; ARDS: acute respiratory distress syndrome. 
RAS: renin-angiotensin system. Red words represent the important turning points in SARS-CoV-2 infection. 
 
 
Clinical presentation of COVID-19 in children  
Liu et al analyzed the data of 6 COVID-19 
confirmed cases out of 366 children, who were 
hospital admitted for respiratory infections. They 
noticed that these 6 children whose median age was 
3 years (range 1-7 years) had moderate to severe 
respiratory distress, four had pneumonia and one 
was admitted to the intensive care unit. However, 
none of them died.20 
The clinical and epidemiological findings of 25 
COVID-19 confirmed children admitted in 100 
hospitals across Hubei province were published. 
Forty percent of the cases were below the age of 3 
years. Eight patients had upper respiratory tract 
infections, 15 had mild pneumonia while 2 patients 
aged 8-12 months old, boys, with underlying 
congenital heart disease, were admitted to the 
intensive care unit and received invasive 
mechanical ventilation, steroids and 
immunoglobulins.21 Wei et al., described nine 
hospitalized infants diagnosed with COVID-19 in 
China, with age range of 1-11 months. Four had 
fever, two mild upper respiratory symptoms and 
one has been asymptomatic with the duration of 
hospital admission ranging between 1 to 3 days. 
None of them required mechanical ventilation.  All 
of them were infected following an infected family 
member.22 COVID-19 has also been reported in 
several neonates although there is no evidence for 
vertical transmission.23 Recently, several infants 
were suspected to die from the disease with no 
confirmed causal relationship. US state of 
Illinois announced the death of an infant under one 
year of age who was positive for 2019-nCoV.24 
By February 10, a total of 398 confirmed 
pediatric versus 10,924 adult cases were reported 
nationwide in China.25 The data on 44,672 COVID-
19 confirmed cases in China revealed that only 
0.9% were less than 10 years of age and 1.2% 
between 10 and 20 years of age.14 Qiu et al., 
analyzed the hospital medical records of 36 children 
(aged 1–16 years; mean age 8.3 [3.5] years) out of 
661 COVID-19 confirmed cases from Ningbo and 
Wenzhou in China. Seventeen (47%) had mild 
(n=7) or no (n=10) symptoms, while 19 (53%) had 
mild pneumonia and no severe or critical cases were 
reported, while pulmonary ground-glass opacities 
were evident in 13 patients (64%). In comparison to 
adults, pediatric patients had a significantly lower 
prevalence of fever (36% for children versus 86% 
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for adults), cough (19% versus 62%), pneumonia 
(53% versus 95%), elevated C-reactive protein (3% 
versus 49%), and severe disease type (0% versus 
23%). However, pediatric and adult groups were 
comparable in terms of leukopenia, lymphopenia 
and elevated myocardial enzymes. Worth to note is 
that COVID-19 pediatric patients had higher 
incidence of pneumonia, but less frequent upper 
respiratory tract symptoms as compared to those 
with H1N1.25 
A larger cohort that included 2143 pediatric 
patients with COVID-19 from China, of whom 731 
were laboratory-confirmed and 1412 were just 
suspected was analyzed. The median age of all 
patients was 7 years (range: 1 month-18 years). 
Cases were classified into asymptomatic infection 
(4.4%), mild (50.9%), and moderate (38.8%) while 
the severe and critical categories accounted for only 
5.9% of cases and one death was encountered in a 
14-year-old boy. Clinical manifestations of 
pediatric patients were generally less severe than 
those of adult patients.27 Another report by Lu et al 
who analyzed the data of 171 children with 
confirmed SARS-CoV-2 of whom 27 were 
clinically and radiologically free, 12 had only 
radiological features of pneumonia and 3 required 
intensive care and mechanical ventilation. The three 
critical patients had underlying health conditions, 
namely leukemia, hydronephrosis and 
intussusception. The 10 months old boy with 
intussusception died 4 weeks after admission with 
multiorgan failure.28 
Among the Italian population, children 
represented 1.2% of 22,512 COVID-19 confirmed 
cases, with no reports of death among children in 
one report.29 In the US, children represented 5% of 
4,226 COVID-19 cases and accounted for less than 
1% of COVID-19 related hospitalizations until 
March 16, 2020 with no ICU admissions or deaths 
among persons aged ≤19 years.30 The death of a 12 
years old Belgian girl, 13 years old boy from UK 
and 16 years old girl from Paris who were all 
confirmed COVID-19 cases were recently reported; 
yet, there are no published details about their 
clinical background.31   
The available data might not reflect the exact 
numbers of 2019-nCoV infected children, but it is 
obvious that children are more common to be 
asymptomatic or have milder symptoms in 
comparison to adults and have significantly lower 




Figure 2. United States cumulative rates of laboratory-confirmed COVID-19-associated hospitalizations 
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What makes children less vulnerable to severe 
and/or fatal COVID-19? 
None of the aforementioned reports convincingly 
explain why children are relatively tolerant to 
COVID-19 but not to other viral infections such as 
Ebola, influenza or measles. However, several 
speculations have emerged. One hypothesis relates 
this difference to a lower degree of maturation and 
function (e.g., binding ability) of the angiotensin 
converting enzyme II (ACE2) which is considered 
to be a cell receptor for the 2019-nCoV, leading to a 
relative resistance to the 2019-nCOV in children.6 
However, this speculation needs further 
investigations to validate. Another speculation 
relates it to the more active innate immune response 
and healthier respiratory tracts in the young 
children because they have not been exposed to as 
much cigarette smoke and air pollution as adults, in 
addition to fewer underlying chronic health 
disorders.11 The presence of associated viral co-
infection and/or respiratory tract bacterial 
colonization might have an impact but this 
assumption is not yet extensively investigated.  
The phenomenon of immunosenescence may be 
involved in the explanation of COVID-19 age 
variability. It refers to the accelerated aging of the 
immune system, with the inability to mount an 
appropriate and effective immune response to 
challenge in the elderly.33,34 With age, there is 
gradual decrease of naïve T cell numbers related to 
thymic involution. The thymus itself undergoes 
structural changes with a progressive decrease in 
the mass of functional tissues, and replacement by 
fat. Aging is also associated with shrinking of the 
TCR repertoire that determines antigenic diversity 
broadness with concomitant increased proportion of 
terminally differentiated oligoclonal effector 
memory T-cell populations. In addition, there is 
loss of the costimulatory receptor CD28, which is 
critical for complete T-cell activation. With aging, 
T cells gradually switch to a pro-inflammatory 
cytokine profile with increased production of IL-6, 
TNF-α and IFN-γ.35-39 All these factors are expected 
to impair the immunological response of the elderly 
against newly encountered pathogens and might 
explain the enhanced COVID-19 cytokine storm 
among this age group. 
Shortened telomere length in blood leukocytes 
might have a role as well. Telomeres are DNA-
protein complexes at the end regions of 
chromosomes, decrease in length with every cell 
division and their shortening is associated with 
impaired immune response to new antigens together 
with increased synthesis of proinflammatory 
cytokines. CD8+ T cells were shown to have a 
higher rate of telomere shortening in comparison to 
other lymphocyte subsets. Advanced aging is 
associated with more prevalence of very short 
telomeres and hence poor immune response.40-45 
Eisenberg et al., investigated leukocyte telomere 
length among young men from 11 European 
countries and observed that Italian men showed the 
shortest while the Belgian had the longest telomere 
length among the studied countries.46 Leukocyte 
telomere length was also found to be significantly 
longer among sub-Saharan Africans than in both 
Europeans and African Americans.47 Furthermore, 
Zhu et al., who investigated 667 adolescents, 
noticed longer telomeres among black adolescents 
in comparison to white controls and girls had longer 
telomeres than boys.48  Noteworthy, males were 
found to have higher rates of COVID-19 related 
morbidity and mortality than females.49  
One may speculate that childhood obligatory 
vaccination may have a role in the mysterious 
under-expression of the disease in the pediatric age 
group. For instance, BCG (bacillus Calmette-
Guérin) vaccine against tuberculosis was assumed 
by investigators from several countries to offer 
some protection. Australian researchers at the 
Murdoch Children's Research Institute in 
Melbourne are fast-tracking to see if a vaccine used 
for decades to prevent tuberculosis can protect from 
COVID-19. The trial of the BCG vaccine will be 
conducted with 4,000 health workers in hospitals 
around Australia to determine if it can mitigate 
COVID-19 symptoms. BCG is known to boost 
human 'frontline' innate immunity for prolonged 
periods following vaccination. Similar trials are 
being conducted in several countries including the 
Netherlands, Germany and the United Kingdom.50 
For instance, a randomized placebo-controlled 
study published in 2018 proved that BCG can 
protect against experimental infection with a 
weakened form of the yellow fever virus.51  
What argues against this assumption is that BCG 
vaccination is compulsory in many countries that 
are bombarded with high rates of mortality from 
COVID-19 including China and Iran. Also, children 
from countries that do not include BCG in their 
vaccination program, including the US and most 
European nations, still have lower rates of 
morbidity and mortality from COVID-19. The 
results of the above-mentioned trials are awaited as 
are trials of specific vaccines against this dreadful 
virus.  
In conclusion, COVID-19 is a highly contagious 
disease and its real burden in children including 
infection and/ or carrier state still needs to be 
identified by screening at a wider scale. The 
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forthcoming years may offer more comprehensive 
explanation to the mysterious lower morbidity and 
mortality of COVID-19 in infants and children who 
should theoretically be vulnerable to emerging 
micro-organisms such as SARS-CoV-2. 
Multinational, epidemiologic and molecular genetic 
studies are needed to identify possible racial 
differences in the Corona viruses’ susceptibility and 
disease outcome. Integrated international efforts are 
needed to defy its global threat to humankind. 
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